Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

Search through Resources

Home

Clinical Updates Calendar

View All Resources

Search through Resources

Optimizing Treatment Selection in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC

Future Directions: Toward Personalized EGFR Therapy in NSCLC

Comparing Intensification Strategies and Toxicity Profiles

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar

TP53 Mutations in EGFR-Mutant and Risk Stratification

Poor Prognostic Factors and Frontline Treatment Selection

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options

Lung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

Keeping Future Options Open: Flexibility Across the EGFR Treatment Journey

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

Building a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLC

Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

The Importance of Combination Therapy: Understanding Chemotherapy’s Role in Modern EGFR+ Treatment

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases

Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors

Lung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care Infographic

FLAME Data and the Role of ctDNA

Understanding the Differences Between Chemotherapeutic Agents: The Misconception Driving Today’s Conversations

Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

Structure-Function–Based Classification System Could Refine TKI Selection for Atypical EGFR-Mutant NSCLC Subsets

EGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape

The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management

Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC

The Evolution of Frontline Therapy in EGFR-Mutant NSCLC

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

TP53 Co-Mutation and the TOP Study

Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options Infographic

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC Infographic

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC

Sequential Erlotinib + Ramucirumab Before Osimertinib Does Not Improve Outcomes in EGFR L858R–Mutant NSCLC

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC

Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC

Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

EGFR-Driven Solid Tumors Preclinical Data

EGFR-Mutated NSCLC: Acquired Resistance

VRN110755 Shows Initial Antitumor Activity Across Dose Levels in EGFR-Mutant NSCLC

Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC

Adding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLC

ctDNA and Real-World Data Guide Strategies to Overcome Acquired Resistance in EGFR-Mutated NSCLC

Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

Remaining Evidence Gaps in EGFR-Mutated NSCLC Care

Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC

Dr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC

Emerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLC

Shared Decision-Making With Chemotherapy in EGFR+ NSCLC

Treatment Intensification Benefits Extend Beyond High-Risk EGFR-Mutated NSCLC

Sunvozertinib Improves PFS Over Chemotherapy in First-Line EGFR Exon 20–Mutant NSCLC

Factors Informing First-Line Treatment Selection in EGFR-Mutated NSCLC

Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC

Top 5 Highlights from ASCO 2026

Sunvozertinib Outperforms Chemotherapy in Frontline EGFR Exon 20 Insertion–Positive Advanced NSCLC

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

Rethinking High-Risk EGFR-Mutant NSCLC

The Emerging Role of ADCs in EGFR-Mutant NSCLC

MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management

Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC

Top 5 Highlights From ELCC 2026

EGFR-Mutated NSCLC Frontline Treatment

VRN110755 in EGFR-Mutant NSCLC

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)

Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis

Breaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLC

EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy

Frontline Decision-Making in EGFR-Mutant NSCLC

Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC